Solid stock: buy or sell?
November 19th, 2019
Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States.
Should I buy Solid stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Solid stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Solid stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 9 ratings published for SLDB stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-19||Svb Leerink||Market Perform||Outperform|
|2019-8-19||Leerink Swann||Market Perform||Outperform|
|2019-5-14||Goldman Sachs Group||Neutral||Sell|
|2019-5-14||Credit Suisse Group||Neutral||Underperform|
|2019-2-8||Svb Leerink||Outperform||Market Perform|
Solid stock analysis
Solid Biosciences climbed an amazing 5.44% and closed at $3.68.
Solid closed today at $3.68 and climbed an amazing 5.44%. Since SMA100d and SMA200d crossed up today, SLDB price climbed $0.19 per share (5.44%). For the last 7 days when SLDB stock price broke down the SMA200d line, it slid $-7.32 per share (-66.55%).
Last week SLDB plunged a dreadful -214.25% in just one week. After sliding a dreadful -214.25% in a week last week, Solid Biosciences closed this week at $3.68 and climbed a phenomenal 4.84%.
Since last week, when SLDB stock price broke down the 40-weeks moving avarage line, it slid $-7.35 per share (-66.64%). Stocks under the 200 days moving average line are usually not recommended for average traders. Since early November when SMA20w and SMA40w crossed up, SLDB price slipped $-7.85 per share (-68.08%).
Solid stock price history
Solid stock went public on January 26th, 2018 with a price of $25.501. Since then, SLDB stock sliced a -85.60%, with a yearly average of -85.60%.
1: Adjusted price after possible price splits or reverse-splits.
Solid stock historical price chart
SLDB stock reached 52-week highs at $35.00, and all-time highs 2018-06-19 with a price of 54.84.
Solid stock price target is $9.30How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We detected 4 price targets for Solid Biosciences stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-5-14||Credit Suisse Group||Downgrades||$7.00||$6.00||-14.3%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Solid Biosciences presented its financial report, posting a very good climb for the Earnings per Share (EPS). Analyst were expecting $-0.58 per share, but Solid posted $-0.67.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Solid Biosciences annual revenues to M dollars from marked in . , its earnings margin (compared to sales) to , that is million.
Quarterly financial resultsReported quarter income marked $-21.92 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Solid Biosciences sales marked a tight movement and stayed steady a nan%. Looking back to recent quarterly results, Solid Biosciences posted 5 negative quarters in a row.
Solid ownershipWhen you are planning to invest in a company, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Solid, 34.71% of all outstanding shares are owned by its staff.
In case of Solid Biosciences stock, 77.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SLDB stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Solid:
|Market cap||$169.3 M|
|Total shares||46.0 M|
|Float shares||11.1 M|
|- Institutional holdings (%)||77.4%|
|- Insider holdings (%)||34.7%|
|Shares in short selling||0.0%|
|Tuesday, November 19th, 2019|
|Day range||$3.33 - $3.80|
|Average true range||$1.16|
|50d mov avg||$10.02|
|100d mov avg||$8.34|
|200d mov avg||$8.30|
Solid performanceTo better understand Solid Biosciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Solid, the benchmark is made against .